Denmark: LEO Pharma to acquire Timber in US

LEO Pharma , a global medical dermatology group, is acquiring US-listed Timber Pharmaceuticals, a clinical-stage biopharmaceutical company. Timber Pharmaceuticals’ lead investigational product candidate, TMB-001, is a topical reformulation of the active ingredient, isotretinoin, which is aimed at treating congenital ichthyosis – a rare skin disease with no approved prescription therapies. The transaction adds an attractive…

You must be a HMI Subscriber to view this content.

Subscribe Now »